Since 2012, September has been celebrated as World Alzheimer’s Month. Back then, and only eleven years ago, an average of 2 out of 3 people had little understanding of Alzheimer's disease and associated dementias.
Below is a brief roundup of news and story ideas from the experts at UCLA Health. For more information on these stories or for help on other stories, please contact us at [email protected].
The three-year, $1.3 million grant from the Administration for Community Living’s Alzheimer’s Disease Program Initiative will support a groundbreaking project designed to advance health equity and improve quality of life for individuals living with or at high risk for Alzheimer’s disease and related dementias and their family caregivers.
A recent study shows that a protein called ABCA7 plays a functional role as a potential biological link between cholesterol and inflammation in Alzheimer’s disease. The new work was published online August 25 in the journal Cells.
Connections among one set of activated neurons in rat brains grew stronger while memories were being formed, but those in another weakened, UT Southwestern Medical Center researchers discovered.
A $750,000 philanthropic grant from the Carl Angus DeSantis Foundation will help FAU develop partnerships and programs that will establish best practice for coordinated care and research for Alzheimer’s disease and related dementias.
El lecanemab ha llamado la atención en todo el mundo por ser el medicamento aprobado recientemente para la enfermedad de Alzheimer y el primer tratamiento aprobado por la FDA para el alzhéimer en más de 20 años.
O lecanemabe recebeu atenção mundial depois de ter sido o medicamento mais recente aprovado para a doença de Alzheimer e o primeiro tratamento aprovado para Alzheimer pela Administração de Alimentos e Medicamentos (Food and Drug Administration, FDA) dos EUA em mais de 20 anos.
مدينة روتشستر، ولاية مينيسوتا — حظى دواء ليكانيماب باهتمام عالمي كأحدث خيار علاجي معتمد للتعامل مع داء الزهايمر وأول دواء معتمد من إدارة الغذاء والدواء الأمريكية منذ أكثر من 20 عامًا. دونانيماب، هو دواء آخر من نفس الفئة في طور المراجعة للحصول على الاعتماد نفسه. ويتوقع أن يُعتمد خلال هذا العام. يقول فيجاي رامانان، دكتور في الطب، حاصل على دكتوراه اختصاصي الأعصاب السلوكي في مايو كلينك في مدينة روتشستر، بولاية مينيسوتا أنه من المهم النظر إلى هذه الخيارات الجديدة كجزء محتمل من خطة علاجية شاملة.
Scientists at Peter the Great St. Petersburg Polytechnic University demonstrated that optogenetic stimulation of hippocampal astrocytes can have a positive effect on the course of the Alzheimer's disease. At the very least, it worked in a mouse model of the disease.
It is a heartbreaking condition that robs children of their ability to walk, talk and recognise their loved ones and now the latest research has revealed the true impact of childhood dementia globally.
The new University of Chicago Healthy Aging & Alzheimer's Research Care (HAARC) Center will focus on building deep multidisciplinary expertise and bridging the gap between scientific disciplines to accelerate breakthroughs in cognitive resilience.
Using gene therapy to treat many neurologic diseases, such as Alzheimer’s and Parkinson’s, has long been a long-sought goal of researchers, but the blood-brain barrier has proven very difficult to cross.
Scientists have opened a new view into the workings of the brain and central nervous system, detecting a diverse set of important molecules known as lipoproteins. The most common protein on the particles is apolipoprotein E; one form of APOE puts people at higher risk of Alzheimer’s disease.
The Richmond, Virginia-based Red Gates Foundation recently committed $50 million to the Fralin Biomedical Research Institute at VTC to accelerate health sciences research at Virginia Tech. The gift is among the largest ever made to the university.
A three-year, $3.4 million grant to investigate how Alzheimer’s disease is connected to multiple chronic diseases has been awarded to UTHealth Houston researchers by the National Institute on Aging, part of the National Institutes of Health.
Scientists at St. Jude Children’s Research Hospital found that a subset of CD8+ T cells in the brain lessens the activation of microglia and limits disease pathology in a model of Alzheimer’s disease.
New research published in the Journal of the American Geriatrics Society indicates that antipsychotics are likely overprescribed and used inappropriately among patients with Alzheimer’s disease and related dementias (ADRD) receiving home health care, and such use is linked to worse patient outcomes.
SMU biology professor Zhihao Wu has received a $1.8 million, 5-year Maximizing Investigators' Research Award (MIRA) from the National Institutes of Health to determine if different quality control pathways in our bodies might be working together to repair damaged components in cells.
Researchers have received a U.S. patent for a novel method to identify therapeutic agents to treat addiction. The invention, related to the fields of pharmacology, medicine, neurology and psychiatry, targets the protein MBLAC1, which the Blakely lab identified as the mammalian form of a gene the group first identified in worms as a modifier of signaling by the neurotransmitter dopamine.
A groundbreaking study led by experts from Indiana University School of Medicine has shed new light on the genetic underpinnings of Alzheimer's disease.
A new Columbia Nursing study analyzes the performance of ADscreen, a computerized speech processing algorithm that is being developed to support clinicians in detecting and monitoring the progression of Alzheimer's disease and related dementias early.
With the help of a new grant from the National Institutes of Health for more than $2.6 million, Assistant Professor Timothy Huang, Ph.D., will continue his research on the role of the brain’s immune cells on the risk of developing Alzheimer’s disease.
Scientists at Wake Forest University School of Medicine are reporting results from a Phase I trial in an area of promising research for Alzheimer's disease—cellular senescence.
Neuroscience researchers at Wayne State University published a review article that confirms the usefulness of neurofilament light (NfL) blood levels to predict the likelihood and rate of progression of neurodegeneration in Alzheimer’s disease.
An Indiana University School of Medicine statewide project in collaboration with Indiana University Health was recently funded to support people living with dementia as well as their family care partners find more support and resources, thanks to a new $686,000 grant from the National Institute on Aging IMPACT Collaboratory.
Brent Forester, the Dr. Frances S. Arkin Chair of Psychiatry at Tufts University School of Medicine and psychiatrist-in-chief and chair of the Department of Psychiatry at Tufts Medical Center, focuses his research on geriatric psychiatry and neurocognitive disorders, such as Alzheimer’s disease and related dementias, late-life depression, and older adult bipolar disorder.
John Chappell, a cardiovascular scientist in the Center for Vascular and Heart Research at the Fralin Biomedical Research Institute at VTC, didn't quite believe what he was seeing.
Researchers have identified a way to assess brain activity in sleep that occurs in the earliest stages of Alzheimer’s disease, typically many years prior to developing symptoms of dementia.
En julio, salió al mercado el primer análisis de sangre directo al consumidor diseñado para evaluar el riesgo de un usuario de desarrollar la enfermedad de Alzheimer.
A new study by Indiana University School of Medicine researchers uses more genetically diverse mouse models to study the accumulation and spread of abnormal tau protein deposits in the brain.
Researchers analyzed health information on middle-aged and senior participants in the UK Biobank. They showed that those who took part in adult education classes had a 19% lower risk of developing dementia within five years of follow-up.
Researchers at RUSH are seeking volunteers to explore how a change in diet may improve brain health after a stroke. The study, called NOURISH — short for Nutrition Effects on Brain Outcomes and Recovery in Stroke After Hospitalization — aims to prevent cognitive and memory decline that is common in stroke survivors.
New results from researchers at UC San Diego School of Medicine suggest that intermittent fasting could be an effective treatment approach for Alzheimer’s disease.
In trials, the antipsychotic drug brexpiprazole (Rexulti) failed to provide a clinically meaningful benefit and increased the risk of death. Yet the US Food and Drug Administration (FDA) has fast tracked its approval, making Rexulti the first antipsychotic for treating agitation in elderly patients with dementia.
Only a small percentage of older adults who are in the early stages of Alzheimer’s disease meet the eligibility criteria to receive new monoclonal antibody treatments, drugs that target amyloid-ß plaques in the brain, an early sign of Alzheimer’s disease. The new research is published in the August 16, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. Clinical trial results for these drugs are only available in people in the early symptomatic stages of the disease, mild cognitive impairment or mild dementia due to Alzheimer’s disease.
Prior vaccination against tetanus and diphtheria, with or without pertussis (Tdap/Td); herpes zoster (HZ), better known as shingles; and pneumococcus are all associated with a reduced risk for developing Alzheimer’s disease, according to new research from UTHealth Houston.
Dr. Heather Sandison, a leading expert in Alzheimer's Disease and Related Dementia (ADRD) care, has recently published a groundbreaking study in the Journal of Alzheimer's Disease, highlighting significant improvements in cognitive function among individuals with cognitive decline.
La inteligencia artificial (IA) está capturando la imaginación del público a medida que el ritmo de la innovación se acelera considerablemente y las herramientas de IA fáciles de usar ofrecen nuevas posibilidades para transformar industrias enteras.
A new study published in the Journal of Alzheimer’s Disease by a Virginia Tech Carilion School of Medicine faculty member shows that brain levels of dietary lutein, zeaxanthin, lycopene, and vitamin E in those with Alzheimer’s disease are half those in normal brains. Higher dietary levels of lutein and zeaxanthin have been strongly linked to better cognitive functions and lower risk for dementia or Alzheimer’s disease.
Artificial intelligence (AI) is capturing the public imagination as the pace of innovation accelerates sharply and easy-to-use AI tools offer new possibilities to transform whole industries.
Scientists at Université Laval and the University of Lethbridge have succeeded in reversing certain cognitive manifestations associated with Alzheimer's disease in an animal model of the disease.
Promising preclinical results from UC San Diego show hematopoietic stem cell therapy was effective in rescuing memory loss, neuroinflammation and beta amyloid build-up in a mouse model of Alzheimer’s disease.
People who take acid reflux medications called proton pump inhibitors for four-and-a-half years or more may have a higher risk of dementia compared to people who do not take these medications, according to new research published in the August 9, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. This study does not prove that acid reflux drugs cause dementia; it only shows an association.
A team from the University of Geneva (UNIGE) and the Geneva University Hospitals (HUG) has demonstrated that tau PET - a novel imaging technique for visualising the tau protein - can predict cognitive decline in patients much better than the imaging techniques normally used.